<DOC>
	<DOC>NCT02810964</DOC>
	<brief_summary>The purpose of this study is to determine if taking a sulforaphane nutraceutical versus a placebo will reduce symptoms of schizophrenia when used in addition to standard antipsychotic medications.</brief_summary>
	<brief_title>Sulforaphane to Reduce Symptoms of Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Sulforafan</mesh_term>
	<criteria>Capacity for written informed consent Age 1865 years, inclusive Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM5) diagnosis of schizophrenia or schizoaffective disorder as determined by the Structured Clinical Interview for DSM5 Disorders (SCID5) Currently an outpatient at time of screening Residual psychotic symptoms of at least moderate severity as evidenced by one or more Positive and Negative Syndrome Scale (PANSS) positive symptom scores, and/or PANSS negative symptom scores of 4 or higher; or a PANSS total score of 50 or higher, containing at least three positive or negative items with scores of 3 or higher at the screening visit Receiving antipsychotic medication for at least 8 weeks prior to enrolling in the study with no antipsychotic medication changes within the previous 21 days from visit 2 (week 0) Conformance to PORT Treatment Recommendation about Maintenance Antipsychotic Medication Dose Proficient in the English language Participated previously in one of our screening studies Any clinically significant or unstable medical disorder as determined by the principal investigator and/or the study physician (e.g., HIV infection or other immunodeficiency condition (such as receiving chemotherapy), uncontrolled diabetes, congestive heart failure) DSM5 diagnosis of intellectual disability or comparable diagnoses determined by previous versions of the DSM DSM5 diagnosis of a moderate or severe substance use disorder, except for caffeine or tobacco, within the last three months prior to the screening visit. If the patient has a positive drug toxicity screen at the time of visit 1 (screening) further evaluation by the investigator will be done of the substance use to determine eligibility. Any current use of a broccoli supplement (e.g., AvmacolÂ® or other health food broccoli supplement) Participated in any investigational drug trial in the past 30 days prior to the screening visit Pregnant, planning to become pregnant, or breastfeeding during the study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizoaffective Disorder</keyword>
	<keyword>Sulforaphane</keyword>
	<keyword>Sulforaphane supplement</keyword>
</DOC>